-
Future Medicinal Chemistry Sep 2017Resistances to antibiotics employed for treatment of infectious diseases have increased to alarming numbers making it more and more difficult to treat diseases caused by... (Review)
Review
AIM
Resistances to antibiotics employed for treatment of infectious diseases have increased to alarming numbers making it more and more difficult to treat diseases caused by microorganisms resistant to common antibiotics. Consequently, novel methods for successful inactivation of pathogens are required. In this instance, one alternative could be application of light for treatment of topical infections. Antimicrobial properties of UV light are well documented, but due to its DNA-damaging properties use for medical purposes is limited. In contrast, irradiation with visible light may be more promising.
METHODS
Literature was systematically screened for research concerning inactivation of main oral bacterial species by means of visible light.
RESULTS
Inactivation of bacterial species, especially pigmented ones, in planktonic state showed promising results. There is a lack of research examining the situation when organized as biofilms.
CONCLUSION
More research concerning situation in a biofilm state is required.
Topics: Aggregatibacter; Anti-Infective Agents; Bacteria; Escherichia coli; Fusobacterium; Humans; Light; Mouth; Porphyromonas; Prevotella; Staphylococcus; Streptococcus
PubMed: 28792235
DOI: 10.4155/fmc-2017-0051 -
Infection & Chemotherapy Dec 2017HACEK is a rare cause of prosthetic valve endocarditis (PVE). We describe 42-year-old male patient who presented with Aggregatibacter aphrophilus PVE and cerebral...
HACEK is a rare cause of prosthetic valve endocarditis (PVE). We describe 42-year-old male patient who presented with Aggregatibacter aphrophilus PVE and cerebral infarct. A. aphrophilus was isolated from his blood cultures as the sole pathogen, which was confirmed by subsequent 16S rRNA sequencing. He was treated with valve replacement surgery and an 8 week course of pathogen-directed antibiotic therapy and followed for 20 months without recurrence.
PubMed: 28608662
DOI: 10.3947/ic.2017.49.4.282